Metformin and risk of gingival/periodontal diseases in diabetes patients: A retrospective cohort study
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Endocrinology"
DOI: 10.3389/fendo.2022.1036885
Abstract: Aim To compare the risk of gingival and periodontal diseases (GPD) between ever users and never users of metformin in patients with type 2 diabetes mellitus. Methods The Taiwan’s National Health Insurance database was used… read more here.
Keywords: ever users; periodontal diseases; risk; gingival periodontal ... See more keywords
Pioglitazone Has a Null Association with Inflammatory Bowel Disease in Patients with Type 2 Diabetes Mellitus
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceuticals"
DOI: 10.3390/ph15121538
Abstract: Pioglitazone shows potential benefits in inflammatory bowel disease (IBD) in preclinical studies, but its effect in humans has not been researched. We used a nationwide database of Taiwan’s National Health Insurance to investigate whether pioglitazone… read more here.
Keywords: ever users; disease; inflammatory bowel; pioglitazone ... See more keywords
The Risk of Age-Related Macular Degeneration Is Reduced in Type 2 Diabetes Patients Who Use Metformin
Sign Up to like & getrecommendations! Published in 2023 at "Pharmaceuticals"
DOI: 10.3390/ph16020224
Abstract: Background: Whether metformin may reduce the risk of age-related macular degeneration (AMD) requires confirmation. This study compared the risk of AMD between ever users and never users of metformin matched on propensity score (PS) in… read more here.
Keywords: ever users; risk; never users; risk age ... See more keywords